Duration of treatment Indefinite Sample Clauses

Duration of treatment Indefinite. Adverse effects The adverse reactions related to somatostatin analogues are predominantly gastrointestinal and common effects include diarrhoea or constipation, abdominal pain, nausea, flatulence, cholelithiasis, gall bladder sludge. Less common side effects may include: asthenia, fatigue, increased bilirubin, hot flushes, leg pain, malaise, headache, tenesmus, vomiting, abnormal glucose tolerance, hyperglycaemia, decreased libido, somnolence, pruritus, increased sweating. Local skin reactions may occur at injection sites.
Sample 1Sample 2Sample 3
Duration of treatment Indefinite. Adverse effects Very common (≥1/10): • Congestive heart failure, increased plasma creatinine, prolonged QTc interval Common (≥1/100 to <1/10): • Bradycardia, diarrhoea, vomiting, nausea, abdo pain, dyspepsia, LFT abnormalities, rashes, pruritus, fatigue, asthenia Uncommon (≥1/1,000 to <1/100): • Dysgeusia, erythemas, eczema, photosensitivity reaction, allergic dermatitis, dermatitis, Interstitial lung disease including pneumonitis and pulmonary fibrosis Rare (≥1/10,000 to <1/1,000): • Ageusia, hepatocellular liver injury (including life-threatening acute liver failure), Vasculitis, including leukocytoclastic vasculitis, Anaphylactic reactions including angioedema In clinical trials, the most frequently observed adverse reactions with dronedarone 400 mg po bd were diarrhoea, nausea, vomiting, fatigue and asthenia. Refer to the SPC for a full list of adverse effects & further information xxxx://xxx.xxxxxxxxx.xxx.xx
Sample 1Sample 2
Duration of treatment Indefinite as long as treatment is considered appropriate by specialist (epilepsy specialist, adult or paediatric neurologist) When used for treatment of Epileptic spasms ( West Syndrome) there is a Trust approved guideline which follows regional ( CEWT: Children’s Epilepsy Workflow in Trent) guidelines regarding length of treatment ( see appendix 3)
Sample 1Sample 2
Duration of treatment Indefinite. Adverse effects Apomorphine is usually highly emetogenic, so all patients are treated with domperidone 10mg TDS starting at least 3 days prior to initiation of therapy. Domperidone will be gradually withdrawn. Domperidone should be avoided in patients who are taking concomitant medication known to cause QT prolongation, an ECG should be performed prior to using domperidone and the decision to use made by the specialist. It is sometimes possible to withdraw this after a couple of months. The domperidone may also prevent/reduce postural hypotension. See MHRA drug safety update (May 2014) Apomorphine may provoke;  nausea and vomiting  postural hypotension – usually only transient on initiation of treatment  Neuro-psychiatric disturbances, e.g. hallucinations, delusions and confusional states.  Inflammation and formation of nodules at injection sites.  dyskinesias (abnormal involuntary movements)  eosinophilia in up to 10% of patients  Coomb’s reaction in 6% of patients  haemolytic anaemia and thrombocytopenia
Sample 1
Duration of treatment Indefinite. Adverse effects Rare or very rare Alopecia; angina pectoris (more common at excessive dosage); arrhythmia (more common at excessive dosage); diarrhoea (more common at excessive dosage); heat intolerance; muscle cramps; muscle weakness; palpitations (more common at excessive dosage); tachycardia (more common at excessive dosage); vomiting (more common at excessive dosage) Frequency not known Agitation; fever; flushing; headache; hyperhidrosis; insomnia (more common at excessive dosage); oedema; restlessness (more common at excessive dosage); skin reactions; tremor (more common at excessive dosage); weight decreased For a full list of all potential adverse event please refer to the spc
Sample 1
Duration of treatment Indefinite. Adverse effects Very common (≥1/10): Hot flush*, injection site adverse events Common (≥1/100 to <1/10): anaemia*, weight increase*, insomnia, dizziness, headache, diarrhoea, nausea, liver transaminases increased, hyperhidrosis (inc. night sweats)*, rash, musculoskeletal pain & discomfort, gynaecomastia*, testicular atrophy*, erectile dysfunction*, chills, pyrexia, fatigue*, influenza-like illness *known physiological consequence of testosterone suppression
Sample 1

Related to Duration of treatment Indefinite

  • Equality of Treatment Unless otherwise provided in this Agreement, the persons specified in Article 3, who ordinarily reside in the territory of a Contracting State, shall receive equal treatment with nationals of that Contracting State in the application of the legislation of that Contracting State.

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State. (2) In addition, each Contracting Party shall accord to investors of the other Contracting Party, including in respect of returns on their investments, treatment which shall not be less favourable than that accorded to investors of any third State. (3) The provisions of paragraphs (1) and (2) above shall not be construed so as to oblige one Contracting Party to extend to the investors of the other the benefit of any treatment, preference or privilege resulting from: (a) Any existing or future free trade area, customs unions, monetary union or similar international agreement or other forms of regional cooperation to which one of the Contracting Parties is or may become a party, or (b) Any matter pertaining wholly or mainly to taxation.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • PRESERVATION OF TAX AND ACCOUNTING TREATMENT Except as contemplated by this Agreement or the Registration Statement, after the Funding and Consummation Date, TCI shall not and shall not permit any of its subsidiaries to undertake any act that would jeopardize the tax-free status of the organization, including without limitation: (a) the retirement or reacquisition, directly or indirectly, of all or part of the TCI Stock issued in connection with the transactions contemplated hereby; or (b) the entering into of financial arrangements for the benefit of the Stockholders.

  • Certification Regarding Prohibition of Boycotting Israel (Tex Gov. Code 2271)

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Recognition of the U.S. Special Resolution Regimes (a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. (b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

  • Equal Treatment of Purchasers No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

  • Certain Securities Law Matters (a) Interest Holder is acquiring its New Black Knight Shares as principal for its own account and not with a view to the distribution thereof within the meaning of the Securities Act. (b) Interest Holder understands that the New Black Knight Shares issued to it will not be transferable except (i) pursuant to an effective registration statement under the Securities Act, (ii) pursuant to an available exemption from, or in a transaction not subject to, the Securities Act as evidenced by receipt by the Company of a written opinion of counsel for Interest Holder reasonably satisfactory to the Company to the effect that the proposed transfer is exempt from the registration requirements of the Securities Act and relevant state securities Laws, or (iii) pursuant to Rule 144 under the Securities Act (“Rule 144”). Applicable U.S. restrictive legends shall be placed on certificates representing the New Black Knight Shares to be delivered to Interest Holder at the Exchange Closing, substantially as follows: “THE SHARES OF COMMON STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THESE SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH REGISTRATION OR QUALIFICATION IS NOT REQUIRED.”

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.